Analysis and data insight - Articles - Page 199

Money raised by biopharma: 2020 vs. 2019

March 27, 2020

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Biopharma money raised: Jan. 1-March 26, 2020

March 27, 2020

Year-to-date money raised in public, private and other financings of biopharma companies.

Biopharmaceutical collaborations: February 2020

March 27, 2020

Biopharma licensings, joint ventures and collaborations, including: Achaogen, Advaxis, Aimmune, Aptevo, Aradigm, Astrazeneca, Atreca, Bicycle, Biogen, Caribou, Catalent, Cellectis, Cipla, Clover, Collegium, Curis, Cytodyn, Daewoong, Dyadic, Eisai, Evotec, Eyepoint, Genentech, Glenmark, Grifols, GSK, Hanmi, Hikma, Hollister, Hummingbird, Icagen, Immunos, Innocare, Janssen, Jounce, Karuna, Karyopharm, Kissei, Ligand, Luye, Medivir, Merck, Mylan, Nanostring, Norgine, Noxopharm, Otologic, Paratek, Pfizer, Portola, Probiogen, Redhill, Roche, Sangamo, Sarepta, Tetra, Trianni, Wize, Wockhardt, Wuxi, Xencor, Zeria, Zy.

Illustration of big fish eating three smaller fish

Completed biopharmaceutical mergers & acquisitions: February 2020

March 27, 2020

Completed biopharma M&As, including: Aevi Genomic Medicine, Anika, Arthrosurface, Attenua, Aytu, Cerecor, Coda, Dermira, Eli Lilly, Innovus, Promedior, Pvp, Roche, Takeda.

Collaborations between biopharmaceutical companies and government/nonprofit entities: February 2020

March 27, 2020

Deals between biopharma companies and government or nonprofit entities, including: AB Biotics, ACT Genomics, Active Biotech, Active Motif, Agex, Be Cool, Benevolentai, Berg Pharma, Berkeley Lights, Beroni, Biomarin, Bridge, Cellular Biomedicine, Chugai, Cocrystal, Dianomi, Dyadic, Enochian, Entourage Phytolab, Erytech, Evgen, Exicure, FDA, Gemini, Generex, Genprex, Gibson Oncology, Gilead Sciences, GSK, Innovation, J&J, Medigen, NIH, Novartis, Oncologie, Orgenesis, Sanofi Pasteur, Sapphire, Synspira, Theratechnologies, Toa Eiyo, Tonix, VBL, Venturis, WPD.

Biggest gainers and losers for the week of March 23-27, 2020

March 27, 2020

The top 10 biopharma stock gainers and losers for the week.

'It's really not going to scale'

Companies face challenges with increasing clinical trial data sources

March 24, 2020

By Brian Orelli

A survey of 149 companies by Tufts Center for the Study of Drug Development found more than two-thirds of clinical trial sponsors were using or piloting at least four different data sources in their clinical trials.

Gene and cell therapies being developed for rare diseases

March 23, 2020

By Peter Winter

The Rare Disease Day, which takes place at the end of February each year, is designed to focus global attention on the need for therapies to treat patients suffering from devastating rare diseases. The most recent event represented the 13th year it has been held. Over that period, research and development in the area has come a long way, and there are now 420 companies around the world that are active in developing regenerative medicines and advanced therapies for the treatment of rare diseases, according to a new report released by the Alliance for Regenerative Medicine (ARM).